For both flow rates, increasing the dose of CXCL12 from 1600 ng/mL to 2400 ng/mL promoted the migration of U87-GFP GBM cells at 120 h in both flow directions (Fig 5). The gene discussed is CXCL12; the disease is glioblastoma.